Abstract:Host cellular receptors are key determinants of virus tropism and pathogenesis. Virus utilizes multiple receptors for attachment, entry, or specific host responses. However, other than ACE2, little is known about SARS-CoV-2 receptors. Furthermore, ACE2 cannot easily interpret the multi-organ tropisms of SARS-CoV-2 nor the clinical differences between SARS-CoV-2 and SARS-CoV. To identify host cell receptors involved in SARS-CoV-2 interactions, we performed genomic receptor profiling to screen almost all human membrane proteins, with SARS-CoV-2 capsid spike (S) protein as the target. Twelve receptors were identified, including ACE2. Most receptors bind at least two domains on S protein, the receptor-binding-domain (RBD) and the N-terminal-domain (NTD), suggesting both are critical for virus-host interaction. Ectopic expression of ASGR1 or KREMEN1 is sufficient to enable entry of SARS-CoV-2, but not SARS-CoV and MERS-CoV. Analyzing single-cell transcriptome profiles from COVID-19 patients revealed that virus susceptibility in airway epithelial ciliated and secretory cells and immune macrophages highly correlates with expression of ACE2, KREMEN1 and ASGR1 respectively, and ACE2/ASGR1/KREMEN1 (ASK) together displayed a much better correlation than any individual receptor. Based on modeling of systemic SARS-CoV-2 host interactions through S receptors, we revealed ASK correlation with SARS-CoV-2 multi-organ tropism and provided potential explanations for various COVID-19 symptoms. Our study identified a panel of SARS-CoV-2 receptors with diverse binding properties, biological functions, and clinical correlations or implications, including ASGR1 and KREMEN1 as the alternative entry receptors, providing insights into critical interactions of SARS-CoV-2 with host, as well as a useful resource and potential drug targets for COVID-19 investigation. ### Competing Interest Statement M.L., Z.L., Y.Z. H.G. and Y.X. are listed as inventors on a pending patent application for the newly identified S receptors described in this manuscript. The other authors declare no competing interests.

Network analysis and disease subnets for the SARS-CoV-2/Human interactome

CoVM2: Molecular Biological Data Integration of SARS-CoV-2 Proteins in a Macro-to-Micro Method.

Interactome of human and SARS-CoV-2 proteins to identify human hub proteins associated with comorbidities

Analyzing host-viral interactome of SARS-CoV-2 for identifying vulnerable host proteins during COVID-19 pathogenesis

Interactome Analysis of the Nucleocapsid Protein of SARS-CoV-2 Virus

Interactomic Analyses and a Reverse Engineering Study Identify Specific Functional Activities of One-to-One Interactions of the S1 Subunit of the SARS-CoV-2 Spike Protein with the Human Proteome

Multiscale statistical physics of the Human-SARS-CoV-2 interactome

Structural analysis of SARS-CoV-2 and prediction of the human interactome

Interaction network of SARS-CoV-2 with host receptome through spike protein

Proteome-wide data analysis reveals tissue-specific network associated with SARS-CoV-2 infection

SARS-CoV-2 Molecular Network Structure

Constructing a full, multiple-layer interactome for SARS-CoV-2 in the context of lung disease: Linking the virus with human genes and microbes

Network-based community detection of comorbidities and their association with SARS-CoV-2 virus during COVID-19 pathogenesis

Computational modeling of Human-nCoV protein-protein interaction network

SARS-CoV-2-host proteome interactions for antiviral drug discovery

Atlas of interactions between SARS-CoV-2 macromolecules and host proteins

Integrated Interactome and Transcriptome Analysis Reveals Key Host Factors Critical for SARS-CoV-2 Infection.

Integrative COVID-19 biological network inference with probabilistic core decomposition

Structural analysis of SARS-CoV-2 genome and predictions of the human interactome

SARS-CoV-2 Phylointeractomics Reveal Functional Evolution of Its Variants Across Susceptible Human Organs

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing